Amyloid tracer shows diagnostic promise for Alzheimer’s disease

April 2, 2013

The amyloid imaging agent F-18 florbetaben has been moving forward in clinical trials for the diagnosis of Alzheimer’s disease. F-18 florbetaben is from the same stilbene derivative with strong binding potential like that of Amyvid, also known as F-18 florbetapir, which was approved by the FDA in April 2012. The up and coming F-18 florbetaben is showing signs of similar effectiveness, according to research published in the upcoming May issue of The Journal of Nuclear Medicine that presented a dynamic model of amyloid imaging using the tracer.